GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimeric Therapeutics Ltd (ASX:CHM) » Definitions » Institutional Ownership

Chimeric Therapeutics (ASX:CHM) Institutional Ownership : 0.80% (As of Jun. 11, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Chimeric Therapeutics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Chimeric Therapeutics's institutional ownership is 0.80%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Chimeric Therapeutics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Chimeric Therapeutics's Float Percentage Of Total Shares Outstanding is 0.00%.


Chimeric Therapeutics Institutional Ownership Historical Data

The historical data trend for Chimeric Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chimeric Therapeutics Institutional Ownership Chart

Chimeric Therapeutics Historical Data

The historical data trend for Chimeric Therapeutics can be seen below:

2021-01-31 2021-02-28
Institutional Ownership 0.80 0.80

Chimeric Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Chimeric Therapeutics (ASX:CHM) Business Description

Traded in Other Exchanges
Address
62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.

Chimeric Therapeutics (ASX:CHM) Headlines

No Headlines